Posted by Michael Wonder on 25 Jul 2023
ICER to assess treatments for paroxysmal nocturnal haemoglobinuria
25 July 2023 - Report will be subject of CTAF meeting in February 2024; draft scoping document open to public comment until 14 August 2023.
The ICER announced today that it will assess the comparative clinical effectiveness and value of iptacopan (Novartis) and danicopan (Alexion Pharmaceuticals) for the treatment of paroxysmal nocturnal haemoglobinuria.
